Strategic Partnership Alida Biosciences has announced strategic collaborations with Storm Therapeutics and Baylor College of Medicine focused on RNA modification analysis and multiplexed sequencing, presenting joint selling opportunities with collaborators and shared customer bases in oncology and epitranscriptomics.

RNA Modification Lead The company specializes in RNA modification analysis and epitranscriptomics, offering services and tools that target cancer therapies and diagnostics, suggesting a market need for advanced sequencing, profiling, and expression analysis partnerships.

Service Expansions Recent launches such as the EpiPlex Duo-Mod service for concurrent m6A and inosine mapping indicate a product expansion that can be positioned to upsell existing customers to broader RNA modification and expression profiling packages.

SBIR Funding NHGRI SBIR grants totaling four million dollars signal validated research capabilities and potential co-investment signals for customers seeking academically grounded, grant-backed data generation and analysis services.

SMB to Mid-Market Fit With 11-50 employees and revenue in the million-dollar range, AlidaBio is positioned as a nimble provider of specialized RNA analysis at a scale attractive to mid-market biotech firms, contract research organizations, and university-affiliated labs seeking deep RNA modification insights.